ĐẶC ĐIỂM GEN CYP2C19 TRÊN TRẺ EM CÓ CHỈ ĐỊNH ĐIỀU TRỊ TIỆT TRỪ HELICOBACTER PYLORI TẠI BỆNH VIỆN NHI ĐỒNG 1
##plugins.themes.vojs.article.main##
Abstract
Background: The polymorphism of the CYP2C19 gene is directly related to the therapeutic effect of proton pump inhibitors (PPIs) on H. pylori infections.
Objectives: Determine the successful eradication rate of H. pylori and the relationship with genotype, phenotype of the CY2P2C19 gene.
Methods: a descriptive case series of 35 pediatric patients 2 months to less than 16 years of age with an indication for treatment of H. pylori. After at least 4 weeks of antibiotics and 2 weeks of PPIs, eradication was assessed by 13C-UBT breath test or fecal antigen test.
Results: 91.4% of the male patients and 82.9% of the 10 -16 year olds, 1/3 of the children had a family history of gastroduodenal disease. Most (93.4%) had abdominal pain, 60% of anemia. 100% had lesions in the antrum, 94.3% had nodular inflammation and 40% had multifocal ulcers. The successful eradication rate was 62.9%. The successful eradication rate of the EM phenotype (7/14 pediatric patients) was lowest.
Conclusions: Screening for H. pylori should be done properly and should be paid more attention to avoid complications of the disease.
##plugins.themes.vojs.article.details##
Keywords
Gen CYP2C19, Helicobacter pylori, trẻ em, CYP2C19 gene, H. pylori, children
References
[2] Furuta T, Shirai N, Sugimoto M et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5(2):181-202. https://doi.org/10.1517/phgs.5.2.181.27483
[3] Zhao F, Wang J, Yang Y et al. Effect of CYP2C19 Genetic Polymorphisms on the Efficacy of Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis. Helicobacter 2008;13(6):532-541. https://doi.org/10.1111/j.1523-5378.2008.00643.x
[4] Tăng Lê Châu Ngọc. Đặc điểm đề kháng kháng sinh và đáp ứng điều trị trên trẻ viêm dạ dày do Helicobacter pylori Luận văn chuyên khoa cấp II. Trường Đại học Y Dược Thành phố Hồ Chí Minh 2018.
[5] Nasri P, Saneian H, Famouri F et al. Helicobacter pylori infection in pediatrics with gastrointestinal complaints. International journal of physiology, pathophysiology and pharmacology 2022;14(2):118–123
[6] Hassall E, Dimmick JE. Unique features of Helicobacter pylori disease in children. Digestive diseases and sciences 1991;36(4):417-423. https://doi.org/10.1007/bf01298868
[7] Shu X, Ye D, Hu C et al. Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years. Scientific Reports 2022;12(1):17754. https://doi.org/10.1038/s41598-022-21661-y
[8] Khien VV, Thang DM, Hai TM et al. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver 2019;13(5):483-497. https://doi.org/10.5009/gnl18137
[9] Kuo CH, Lu CY, Shih HY et al. CYP2C19 polymorphism influences Helicobacter pylori eradication. World journal of gastroenterology 2014;20(43):16029-16036. https://doi.org/10.3748/wjg.v20.i43.16029
[10] Phillips RH, Whitehead MW, Lacey S et al. Solubility, absorption, and anti-Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: In vitro data Do not predict In vivo efficacy. Helicobacter 2000;5(3):176-182. https://doi.org/10.1046/j.1523-5378.2000.00028.x